91�Թ�

Engineering Professor Michael Sefton has been appointed executive director of , a 91�Թ� initiative that is accelerating discoveries in regenerative medicine research to improve treatments for conditions such as heart failure, diabetes and stroke.  

Sefton, a pioneer in tissue engineering and biomaterials, takes over from Peter Zandstra, who is stepping down to lead a new school of biomedical engineering at the University of British Columbia. 

“Regenerative medicine is a key priority for the 91�Թ�, and Medicine by Design is strengthening our position as a global centre of excellence and innovation in this area,” said Vivek Goel, chair of Medicine by Design’s executive committee and 91�Թ�’s vice-president of research and innovation. “Michael is an internationally recognized expert in the field, and I am delighted he has agreed to lead the next phase of Medicine by Design.” 

Medicine by Design was established in July 2015 with a $114-million grant – the largest single research award in 91�Թ�’s history – from the federal government’s . The initiative builds on 91�Թ�’s rich legacy of contributions to stem cells and regenerative medicine, starting in the early 1960s with the identification of blood stem cells by biophysicist James Till and hematologist Ernest McCulloch.

In its first two years, Medicine by Design has awarded more than $30 million to more than 100 researchers across 91�Թ� and its affiliated hospitals through programs that support a robust pipeline of projects from early stage “new ideas” research to clinical translation and commercialization. Its largest award program funds 20 collaborative teams made up of researchers and clinicians with expertise in life and physical sciences, engineering, medicine and computational biology.

Sefton leads a team project that is focusing on using novel biomaterials to stimulate skeletal muscle to fix itself, a process known as endogenous repair. Other teams are tackling diabetes, blindness, and liver and inflammatory bowel diseases, as well as advancing basic research at the convergence of disciplines ranging from stem cell to computational biology.

“By bringing together outstanding researchers and clinicians from diverse disciplines and giving them the resources they need to tackle big questions, Medicine by Design offers a remarkable opportunity to do high-impact research that has the potential to advance and even redefine key areas of regenerative medicine,” said Sefton, a , the Michael E. Charles Professor of Chemical Engineering and a faculty member in the department of chemical engineering & applied chemistry and the Institute of Biomaterials & Biomedical Engineering (IBBME). 

“I look forward to building on the excellent work Peter has done to foster new collaborations and strategically focus the expertise of our community around critical research and its translation into the clinic.”

Medicine by Design’s other activities include supporting the recruitment of established and emerging researchers to strengthen 91�Թ�’s capacity in key areas such as synthetic biology and immunoengineering, and working closely with and industry to identify and advance discoveries with commercialization potential. It is also building international relationships through its Global Speaker Series, as well as its Summer by Design program, a partnership with the Rotman School of Management and CCRM that has brought a dozen PhD students from peer international universities to Toronto this summer for a series of workshops and conferences. 

Sefton holds degrees in chemical engineering from U of T and the Massachusetts Institute of Technology, and has been at U of T since 1974. He has been active in the preparation of blood compatible materials through heparinization, the microencapsulation of mammalian cells in synthetic polymers and various strategies for vascularizing tissue constructs. 

Sefton has served as director of IBBME and as president of the U.S. Society for Biomaterials. He has received numerous awards including the Founders Award of the U.S. Society for Biomaterials, the Killam Prize in Engineering of the Canada Council for the Arts, and the Acta Biomaterialia Gold Medal. He was elected an international member of the U.S. National Academy of Medicine in 2014 and received the Terumo Global Science Prize in 2016.

Sefton’s five-year term as Medicine by Design’s executive director will begin on July 1, 2017.